A total of 135 batches of the capsules have been recalled from consumers due to fears that the defective drug could cause cardiac arrest, according to federal officials.
Glenmark Pharmaceuticals Inc. has recalled 114 batches of potassium chloride extended-release capsules, and American Health Packaging Co. recalled 21 batches of the same capsules last week on behalf of Blue Point Laboratories Inc.
The voluntary recall was initiated because the capsules may not dissolve and may cause high potassium levels, also known as hyperkalemia, according to the U.S. Food and Drug Administration.
According to the FDA, hyperkalemia can cause arrhythmias and lead to cardiac arrest.
The Glenmark recall was issued last Monday, while the Blue Point recall was issued the following day.
Both capsules are manufactured by Glenmark. The Miami Herald reported.
In both recalls, the FDA stated, “To date, the company has not received any reports from volunteer sources of hyperkalemia or serious adverse events related to this recall.”
The capsules are intended for patients with low potassium levels, also known as hypokalemia. They come in bottles of 100 and 500.
The FDA has released the batch numbers of the products being recalled. Glenmark and Blue Point It is posted on the company’s website.
“Consumers who take the recalled potassium chloride extended-release capsules should consult with their doctor or health care provider before stopping use of the product,” FDA officials advised.
“Consumers should also contact their doctor or health care provider if they experience any problems that may be related to taking or using this medication.”
